Iduna Fichtner, MD

Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

Dr. Iduna Fichtner studied pharmacy in Jena and Halle and acquired several qualifications in the field of experimental pharmacology. She has been working in oncology since 1977. Until 1991 she was department leader at the Central Institute for Cancer Research of Academy of Sciences. From 1992 to 2014 she was employed as senior scientist and head of the group "Experimental Pharmacology" at the Max-Delbrück-Center for Molecular Medicine. Additionally, she has been responsible for Technology Transfer of that institution between 1998 and 2002.

Her main research field is the preclinical evaluation and development of novel potential cancerostatics. For that purpose, several new in vivo models, especially for leukemias, breast, lung and colon carcinomas were established and characterized for clinic-relevance and equipment with molecular targets. Iduna Fichtner has special expertise for pharmacological investigations concerning liposomal and other vesicular drugs, and for the study of immuno- and gene-therapeutics. She has published more than 200 original articles in peer reviewed journals.

Mrs. Fichtner is member of the German Cancer Foundation, the European Organisation for Research and Treatment of Cancer (EORTC) and the American Association for Cancer Research (AACR). Within the EORTC she was elected for three years as chairperson of Screening and Pharmacology Group and as speaker of the joint initiative for the development of NCI/EORTC/CRUK derived anticancer agents. Further on, she is member of the Central European Society for Anticancer Drug Research (CESAR)-EWIV and was elected within that organization as head of the Branch Drug Development in Oncology between 2007 and 2009. And She is member of the Editorial Board of the AACR journal Molecular Cancer Therapeutics.

Iduna Fichtner is the Co-founder of Experimental Pharmacology and Oncology (EPO) GmbH existing since 1997 as spin-off of the MaxDelbrück Center. She works in that SME as Chief Scientific Officer and Consultant and is the scientific leader of several national and international consortia.